[EGFR-targeted therapies: what's new?].
Anti-EGFR molecules with monoclonal antibodies or tyrosine protein kinase inhibitors represent a strategy which remains promising as targeted therapies of cancers, despite some ambiguous results. This review proposes to expose the state of the art concerning the development of anti-EGFR molecules: rationale of this approach, analysis of the results obtained on the one hand by monoclonal antibodies and on the other hand by tyrosine kinase inhibitors. Finally, a presentation is done about possible predictive factors for a relevant use of these molecules in the future.
Vignot
Stéphane
S
Service d'oncologie médicale, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris. stephane.vignot@sls.aphp.fr
Besse
Benjamin
B
Soria
Jean-Charles
JC
Milano
Gérard
G
Spano
Jean-Philippe
JP
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D004791:Enzyme Inhibitors; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases